Polymyxin B sulfate and colistin: old antibiotics for emerging multiresistant gram-negative bacteria.
about
Identification and antimicrobial susceptibility of Alcaligenes xylosoxidans isolated from patients with cystic fibrosisIntravenous colistin in the treatment of sepsis from multiresistant Gram-negative bacilli in critically ill patientsUse of high-performance liquid chromatography to study the pharmacokinetics of colistin sulfate in rats following intravenous administrationAerosolized colistin for the treatment of nosocomial pneumonia due to multidrug-resistant Gram-negative bacteria in patients without cystic fibrosisWhat is the efficacy and safety of colistin for the treatment of ventilator-associated pneumonia? A systematic review and meta-regressionColistimethate sodium for the treatment of chronic pulmonary infection in cystic fibrosis: an evidence-based review of its place in therapySuccessful treatment of extensively drug-resistant Acinetobacter baumannii peritoneal dialysis peritonitis with intraperitoneal polymyxin B and ampicillin-sulbactamEnzyme-responsive polyion complex (PIC) nanoparticles for the targeted delivery of antimicrobial polymers.Mass spectrometric fragmentation of cyclic peptides belonging to the polymyxin and colistin antibiotics studied by ion trap and quadrupole/orthogonal-acceleration time-of-flight technology.The two peptide lantibiotic lacticin 3147 acts synergistically with polymyxin to inhibit Gram negative bacteria.Characterization of nontypable Haemophilus influenzae isolates recovered from adult patients with underlying chronic lung disease reveals genotypic and phenotypic traits associated with persistent infection.Ex-vivo evaluation of alginate microparticles for Polymyxin B oral administration.Identification of a new antimicrobial lysine-rich cyclolipopeptide family from Xenorhabdus nematophila.Polymyxin B identified as an inhibitor of alternative NADH dehydrogenase and malate: quinone oxidoreductase from the Gram-positive bacterium Mycobacterium smegmatis.In vitro antimicrobial effects of aztreonam, colistin, and the 3-drug combination of aztreonam, ceftazidime and amikacin on metallo-beta-lactamase-producing Pseudomonas aeruginosaPolymyxin B, in combination with fluconazole, exerts a potent fungicidal effect.Ciprofloxacin causes persister formation by inducing the TisB toxin in Escherichia coli.Mapping residue-specific contacts of polymyxin B with lipopolysaccharide by saturation transfer difference NMR: insights into outer-membrane disruption and endotoxin neutralization.The first report of Escherichia fergusonii isolated from non-human primates, in Africa.Proteus mirabilis pmrI, an RppA-regulated gene necessary for polymyxin B resistance, biofilm formation, and urothelial cell invasion.Quality control guidelines for testing gram-negative control strains with polymyxin B and colistin (polymyxin E) by standardized methods.Colistin in the 21st century.Pharmacodynamics of polymyxin B against Pseudomonas aeruginosa.Combination therapy with intravenous colistin for management of infections due to multidrug-resistant Gram-negative bacteria in patients without cystic fibrosis.Contemporary assessment of antimicrobial susceptibility testing methods for polymyxin B and colistin: review of available interpretative criteria and quality control guidelines.Structure--activity relationships of polymyxin antibioticsSerratia marcescens arn, a PhoP-regulated locus necessary for polymyxin B resistance.Cholic acid derivatives: novel antimicrobials.Efficacy of colistin versus beta-lactams, aminoglycosides, and rifampin as monotherapy in a mouse model of pneumonia caused by multiresistant Acinetobacter baumannii.Colistin dosing and nephrotoxicity in a large community teaching hospital.Isolation of a Paenibacillus sp. strain and structural elucidation of its broad-spectrum lipopeptide antibiotic.Activity and interactions of antibiotic and phytochemical combinations against Pseudomonas aeruginosa in vitro.Emerging infections in burnsThe threat from the pink corner.Colistin resistance in Acinetobacter baumannii is mediated by complete loss of lipopolysaccharide production.Broad-spectrum antibiotic activity of the arylomycin natural products is masked by natural target mutationsImpact of p-glycoprotein inhibition and lipopolysaccharide administration on blood-brain barrier transport of colistin in miceMulti-drug resistant gram negative infections and use of intravenous polymyxin B in critically ill children of developing country: retrospective cohort study.Colistin methanesulfonate is an inactive prodrug of colistin against Pseudomonas aeruginosa.Macrocyclic drugs and synthetic methodologies toward macrocycles
P2860
Q24550797-2F657CF7-5E64-437C-AD0B-1E68F4B23349Q24651466-E2AACA62-5EEE-4A7D-92F2-9B8B4D54BB4EQ24682618-BBA8C406-5383-4053-9559-09F15087FB7DQ24802824-2393D9C1-069F-4F03-9B39-54143F9F2617Q26999921-C343D05C-FCE5-4B42-8248-7B1B4DD5CCADQ27014993-B8599C7D-8233-43FA-8A25-53C72A199386Q28271359-EF21EC12-73E4-4EB1-B450-EEF222FB53ABQ30384420-F7AE034A-1F67-4ED1-8AAC-3BC60A37A55EQ30831634-06E0900F-0BDD-4BBD-B38D-ABAA2A8A701CQ31140261-A1BE9A14-4E1D-450E-B212-B24B5DF17C3AQ31161151-73E7B383-F919-486C-8899-E2E824A99C0AQ33262949-9C1C2A88-DF79-41C8-8421-8055426FF582Q33431190-B8E67627-368D-4FDE-BC20-DD0C0026D5A8Q33476065-CD3A6896-D15B-4EFB-B30C-DEE912EE7DFCQ33491829-DDE185A8-D5BB-429D-8523-4869E3326589Q33532335-EC75A7A9-09E0-4EA2-B4F4-01AC5E63DBBDQ33534627-21ED3E2B-1026-4D1E-9B68-69B2BDCF59A1Q33648928-5F29C79F-54C6-4A78-B47E-7B312B920D3BQ33753466-36A54CB7-4F05-4601-A2AF-89F40722F404Q33768793-A9E66572-234C-4071-B882-92206A3FBF93Q33825674-3D4F0D62-9126-4F9F-A609-2C12963DCEEAQ33847509-C303701E-11ED-41DE-9005-0DE054580274Q33935368-62047DE3-A7BF-47F4-9922-3D219E315EBAQ33938143-DA54CAF7-2046-4366-889F-DE0F731F6BB0Q33970910-1B942A3A-0E3A-490A-8A6D-3941BB80673AQ34010143-263A417A-A7A7-4EB4-BAA0-F96B4809FE60Q34057453-CE31663C-CCB5-4D20-91CF-6655EAD665BDQ34074698-A198C837-D6BC-4910-B575-BD6D1E234C40Q34109543-C97648EB-37F7-4BFA-9D6A-E71AA4A53882Q34150958-3FB792B8-2F38-4B16-B43F-8293175F6465Q34172665-31FB82C5-0274-4B70-A6C6-A391D1FB2F89Q34187311-639F58FE-3066-4503-BBAD-039569350D21Q34207589-CDDEFA3A-16BC-470D-8D60-AD3023D5B872Q34212044-55101B7A-AD00-4582-A2D8-ADB75EF413FFQ34309451-36F7A745-1EF7-42FB-A803-AC1BC7804FE6Q34412978-9607E3F7-3EB6-41C8-91DA-778EEE042A85Q34529241-84750A0C-288D-4864-9CEC-F36B2EFA0A21Q34676586-FD553C4B-5574-4EA8-B2AB-C626D295DE43Q34680516-9A824FAF-8558-47BE-A087-93CEEE82BE87Q34740721-9646764F-F6EB-4D36-A262-494A510D14FF
P2860
Polymyxin B sulfate and colistin: old antibiotics for emerging multiresistant gram-negative bacteria.
description
1999 nî lūn-bûn
@nan
1999 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Polymyxin B sulfate and colist ...... istant gram-negative bacteria.
@ast
Polymyxin B sulfate and colist ...... istant gram-negative bacteria.
@en
type
label
Polymyxin B sulfate and colist ...... istant gram-negative bacteria.
@ast
Polymyxin B sulfate and colist ...... istant gram-negative bacteria.
@en
prefLabel
Polymyxin B sulfate and colist ...... istant gram-negative bacteria.
@ast
Polymyxin B sulfate and colist ...... istant gram-negative bacteria.
@en
P2093
P356
P1476
Polymyxin B sulfate and colist ...... istant gram-negative bacteria.
@en
P2093
P304
P356
10.1345/APH.18426
P407
P577
1999-09-01T00:00:00Z